TWD 70.8
(0.28%)
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2023 | 89.48 Million TWD | 11.22% |
2022 | 80.45 Million TWD | 131.81% |
2021 | 34.7 Million TWD | -27.41% |
2020 | 47.81 Million TWD | 0.0% |
2019 | - TWD | 0.0% |
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2024 Q2 | 90.89 Million TWD | 0.9% |
2024 Q1 | 90.08 Million TWD | 0.67% |
2023 Q2 | 92.66 Million TWD | 127.76% |
2023 FY | 89.48 Million TWD | 11.22% |
2023 Q4 | 89.48 Million TWD | 0.0% |
2023 Q3 | 89.48 Million TWD | -3.43% |
2023 Q1 | -333.85 Million TWD | -514.94% |
2022 FY | 80.45 Million TWD | 131.81% |
2022 Q4 | 80.45 Million TWD | 0.0% |
2021 FY | 34.7 Million TWD | -27.41% |
2020 FY | 47.81 Million TWD | 0.0% |
2019 FY | - TWD | 0.0% |
Name | Total Liabilities | Total Liabilities Difference |
---|---|---|
Apex Biotechnology Corp. | 500.07 Million TWD | 82.105% |
Sinphar Pharmaceutical Co.,Ltd. | 2.85 Billion TWD | 96.864% |
Panion & Bf Biotech Inc. | 1.32 Billion TWD | 93.242% |
Chunghwa Chemical Synthesis & Biotech Co., Ltd. | 1.82 Billion TWD | 95.087% |
GenMont Biotech Incorporation | 204.05 Million TWD | 56.147% |
Abnova (Taiwan) Corporation | 69.42 Million TWD | -28.899% |
Adimmune Corporation | 3.7 Billion TWD | 97.586% |
Tanvex BioPharma, Inc. | 1.94 Billion TWD | 95.393% |
Polaris Group | 1.46 Billion TWD | 93.891% |
Energenesis Biomedical CO.,LTD. | 24.58 Million TWD | -263.961% |
PELL Bio-Med Technology Co. Ltd. | 236.76 Million TWD | 62.204% |